SCHEMBL927264

SCHEMBL927264

Cc1ccc(S(=O)(=O)C(Cl)C(=O)[C@@H](N)Cc2ccccc2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALPI P09923 1/20 0.46
PKM P14618 1/20 0.46
PTGS1 P23219 1/20 0.46
XIAP P98170 1/20 0.46
SLC7A5 Q01650 1/20 0.46
GAA P10253 1/20 0.46
BCHE P06276 1/20 0.43
ACHE P22303 1/20 0.43
CA2 P00918 3/20 0.42
CA7 P43166 2/20 0.42
CA9 Q16790 2/20 0.41
CA1 P00915 1/20 0.41
CA4 P22748 1/20 0.41
SLC15A1 P46059 1/20 0.41
KMT2A Q03164 1/20 0.41
MMP9 P14780 2/20 0.41
CA12 O43570 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
ATM Q13315 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11024973 0.88 GAA (0.45) ALPIPKMPTGS1XIAPSLC7A5
SCHEMBL3939051 0.82 GAA (0.44) ALPIPKMPTGS1XIAPSLC7A5
SCHEMBL27752802 0.82 MMP9 (0.48) ALPIPKMPTGS1XIAPSLC7A5
SCHEMBL789966 0.81 GAA (0.44) ALPIPKMPTGS1XIAPSLC7A5
SCHEMBL27084167 0.81 GAA (0.44) ALPIPKMPTGS1XIAPSLC7A5
Dl-Phenylalanine SCHEMBL18191199 0.77 SLC7A5 (0.63) ALPIPKMPTGS1XIAPSLC7A5
Phenylalanine SCHEMBL10429981 0.77 SLC7A5 (0.63) ALPIPKMPTGS1XIAPSLC7A5
Dl-Phenylalanine SCHEMBL28023088 0.77 SLC7A5 (0.63) ALPIPKMPTGS1XIAPSLC7A5
Phenylalanine SCHEMBL18191186 0.77 SLC7A5 (0.63) ALPIPKMPTGS1XIAPSLC7A5
SCHEMBL23489731 0.76 MMP9 (0.53) GAABCHEACHECA2CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11209440-B2 T cell balance gene expression, compositions of matters and methods of use thereof THE BROAD INSTITUTE, INC. 2021-12-28 US disclosed
US-20180187190-A1 NEW CRISPR ASSAYS ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM (NL) 2018-07-05 US disclosed
US-9840532-B2 5′-substituted nucleoside compounds ELI LILLY AND COMPANY (US) 2017-12-12 US disclosed
US-20160377631-A1 T CELL BALANCE GENE EXPRESSION, COMPOSITIONS OF MATTERS AND METHODS OF USE THEREOF THE BRIGHAM AND WOMEN'S HOSPITAL, INC. 2016-12-29 US disclosed
US-20160326208-A1 5'-SUBSTITUTED NUCLEOSIDE COMPOUNDS ELI LILLY AND COMPANY 2016-11-10 US disclosed
US-20130252924-A1 Compounds and Methods for Treating Pain AKRON MOLECULES GMBH (AT) 2013-09-26 US disclosed
US-8426150-B2 Process for differential polypeptides detection and uses thereof LI RONGXIU (CN) 2013-04-23 US disclosed
US-20110020836-A1 PROCESS FOR DIFFERENTIAL POLYPEPTIDES DETECTION AND USES THEREOF LI RONGXIU 2011-01-27 US disclosed
WO-2010133173-A1 PROCESS FOR DIFFERENTIAL POLYPEPTIDES DETECTION AND USES THEREOF LI RONGXIU (CN) 2010-11-25 WO disclosed
US-5578477-A SCREENING FOR ANTICANCER DRUGS, SOURCE OF PURE ENZYME ARCH DEVELOPMENT CORPORATION (US) 1996-11-26 US disclosed
US-5173405-A USE OF ARSENITE TO REVERSIBLY BLOCK STEROID BINDING TO GLUCOCORTICOID RECEPTORS IN THE PRESENCE OF OTHER STEROID RECEPTORS THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 1992-12-22 US disclosed
WO-1991011713-A1 ARSENITE USED TO REVERSIBLY BLOCK STEROID BINDING TO GLUCOCORTICOID RECEPTORS IN THE PRESENCE OF OTHER STEROID RECEPTORS THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, UNITED STATES DEPARTMENT OF COMMERCE (US) 1991-08-08 WO disclosed
EP-0320148-A1 Analogs of fibroblast growth factor AMGEN INC. (US) 1989-06-14 EP disclosed
WO-1989004832-A1 ANALOGS OF FIBROBLAST GROWTH FACTOR AMGEN INC. (US) 1989-06-01 WO disclosed
EP-0263903-A1 Method for preparing specific inhibitors of virus-specified proteases E.I. DU PONT DE NEMOURS AND COMPANY (US) 1988-04-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160326208-A1 5'-SUBSTITUTED NUCLEOSIDE COMPOUNDS NT5C3B, MCL1, NSUN2 ALPI 3054/4885PKM 2395/4885PTGS1 3464/4885
US-20130252924-A1 Compounds and Methods for Treating Pain TRPV1, ACHE, OPRL1 ALPI 1890/4885PKM 1281/4885PTGS1 39/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.